1. Scrip
  2. >>Therapy Areas

BeiGene’s PD-1 Remains Solid In First Global Pivotal Study

Positive Interim Data In Later-Line NSCLC

 
• By Ian Haydock

Tislelizumab meets overall survival endpoint in later-line NSCLC at planned interim analysis, but faces exploding competition in the Chinese immuno-oncology sector.

Doctor examining at lungs radiograph x-ray film of patient in operation room. medical concept.
Another Positive Interim Readout For Tislelizumab • Source: Shutterstock

BeiGene, Ltd.’s tislelizumab has met its overall survival primary endpoint in a Phase III trial for later-line use in non-small cell lung cancer (NSCLC), in what is the first positive global pivotal clinical trial result for the Chinese firm’s anti-PD-1 antibody.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Anticancer

More from Therapy Areas

Zai’s R&D Head Touts ‘Beauty’ Of Novel Internal Assets

 
• By Dexter Jie Yan

Two potentially first-in-class molecules signify Zai Lab’s renewed drive for the in-house discovery of drugs that it requires “to be innovative, differentiated and to have the potential to make a big difference for patients,” its global R&D head tells Scrip.

J&J’s Imaavy Approval Is The Starting Line For Pipeline-In-A-Product Strategy

 
• By Jessica Merrill

The company’s FcRn inhibitor nipocalimab was approved by the US FDA for generalized myasthenia gravis (gMG), where it will join a competitive market.

GSK Chief Optimistic About BD Despite Volatile Environment

 
• By Kevin Grogan

Emma Walmsley tells Scrip that the "biotech market is under a certain degree of pressure," so reasonably priced deals are available.